29 completed, 15 unknown, 12 recruiting, 8 not yet recruiting. 82 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 82 | Completed 29, Unknown 15, Recruiting 12, Not yet recruiting 8, Terminated 6, Withdrawn 6, Active not recruiting 5, Enrolling by invitation 1 |
Follow Neoplasms, Nerve Tissue: new trials by email Literature Review of Neoplasms, Nerve Tissue trials Research Report on Neoplasms, Nerve Tissue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Zoster Vaccination in Glioblastoma Patients Additional vaccination against shingles (herpes zoster), Standard of care treatment without additional vaccination - Glioblastoma (GBM) | Phase 4 | Not yet recruiting | University Hospital, Essen | 230 | 2027-01-02 | 2026-04-23 |
| A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India Nivolumab + Relatlimab - Unresectable Melanoma, Metastatic Melanoma | Phase 4 | Not yet recruiting | Bristol-Myers Squibb | 40 | 2026-11-15 | 2026-08-12 |
| A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma Iparomlimab and Tuvonralimab Injection (QL1706), OH2 Injection(Recombinant Human GM-CSF Oncolytic Type II Herpes Simplex Virus) - Melanoma, Acral Melanoma | Phase 4 | Not yet recruiting | Peking University Cancer Hospital & Institute | 76 | 2026-10-01 | 2026-10-02 |
| Impact of Dysport on PMFF Donor Scar Abobotulinumtoxin-A, Control- Saline injection - Skin Cancer Excision Site, Basal Cell Carcinoma | Phase 4 | Not yet recruiting | Vanderbilt University Medical Center | 50 | 2026-09-14 | 2026-08-26 |
| Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors Desmopressin (DDAVP), Control - Craniopharyngiomas, Pituitary Macroadenoma | Phase 4 | Enrolling by invitation | Zhaoyun Zhang | 152 | 2026-06-02 | 2026-07-17 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| Safety and Efficacy of Belzutifan in Preoperative Preparation for Patients With Pheochromocytoma/Paraganglioma (PPGL) Belzutifan - Pheochromocytoma and Paraganglioma (PPGL) | Phase 4 | Recruiting | Longfei Liu，MD | 20 | 2026-04-01 | 2026-10-30 |
| Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates - AML (Acute Myeloid Leukemia), Glioma | Phase 4 | Recruiting | Rigel Pharmaceuticals | 16 | 2026-02-23 | 2026-08-11 |
| Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms Surufatinib - Neuroendocrine Tumors, Neuroendocrine Neoplasms | Phase 4 | Recruiting | Shanghai Zhongshan Hospital | 350 | 2025-11-11 | 2025-12-19 |
| Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib Encorafenib & Binimetinib Treatment - Melanoma BRAF V600E/K Mutated | Phase 4 | Withdrawn | SRH Wald-Klinikum Gera GmbH | 2025-08-01 | 2026-04-21 | |
| A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma Irinotecan Hydrochloride Liposome Injection, 5-FU, LV - Neuroendocrine Carcinomas (NEC) | Phase 4 | Not yet recruiting | Beijing GoBroad Hospital | 45 | 2025-06-20 | 2025-06-11 |
| Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy Gamma Tile-Surgically Targeted Radiation Therapy (STaRT), Stereotactic Radiation Therapy - Glioblastoma | Phase 4 | Withdrawn | GT Medical Technologies, Inc. | 2025-05-01 | 2025-04-10 | |
| Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis Atorvastatin, Placebo - Atherosclerosis, Melanoma | Phase 4 | Not yet recruiting | Erasmus Medical Center | 140 | 2025-02-01 | 2025-01-22 |
| Evaluation of Neuroma Perfusion with Indocyanine Green Fluorescence Angiography Indocyanine green - Neuroma, Neuroma Amputation | Phase 4 | Withdrawn | Northwestern University | 2024-12-28 | 2025-01-01 | |
| Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy Assessment, Questionnaire Administration, Telemedicine Visit - Astrocytoma, IDH-Mutant, Glioblastoma | Phase 4 | Completed | Mayo Clinic | 30 | 2024-10-07 | 2026-04-29 |
| Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE Brain Imaging with [Cu64]DOTATATE, Radio-guided Surgery With Neoprobe Utilization - Meningioma | Phase 4 | Recruiting | Weill Medical College of Cornell University | 20 | 2024-09-11 | 2026-02-27 |
| Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma Irinotecan liposomes combined with cisplatin/carboplatin - Neuroendocrine Tumors | Phase 4 | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 20 | 2024-07-01 | 2024-07-03 |
| Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. Naxitamab - Neuroblastoma | Phase 4 | Not yet recruiting | SciClone Pharmaceuticals | 62 | 2023-10-31 | 2023-09-21 |
| Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients Somatostatin analog - Gastroenteropancreatic Neuroendocrine Tumor | Phase 4 | Recruiting | University Hospital, Antwerp | 270 | 2023-06-28 | 2024-06-14 |
| Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma Anlotinib Hydrochloride Capsule - Medullary Thyroid Cancer | Phase 4 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 360 | 2023-06-19 | 2023-07-25 |
Showing 20 of 82. Sign in to see all of them.
Melanoma (27) · Neuroendocrine Tumors (15) · Neoplasms (9) · Glioblastoma (8) · Glioma (7) · Neoplasm Metastasis (7) · Lung Neoplasms (6) · Brain Neoplasms (4) · Breast Neoplasms (4) · Carcinoma, Medullary (4) · Carcinoma, Non-Small-Cell Lung (4) · Neuroblastoma (4) · Pheochromocytoma (4) · Meningioma (3) · Neuroma (3)
Neoplasms by Histologic Type (82) · Neoplasms, Germ Cell and Embryonal (75) · Neuroectodermal Tumors (75) · Neoplasms (73) · Neoplasms by Site (47) · Neuroendocrine Tumors (42) · Neoplasms, Glandular and Epithelial (33) · Nevi and Melanomas (31) · Skin Diseases (28) · Skin and Connective Tissue Diseases (28) · Skin Neoplasms (24) · Neoplasms, Neuroepithelial (18) · Nervous System Diseases (16) · Carcinoma (14)
Carboplatin (4) · Nivolumab (4) · Octreotide (4) · Blood Specimen Collection (3) · Cisplatin (3) · Everolimus (3) · Granulocyte-Macrophage Colony-Stimulating Factor (3) · aldesleukin (3) · lanreotide (3) · Etoposide (2) · Gentamicins (2) · Ipilimumab (2) · Phenoxybenzamine (2) · Propofol (2) · Sevoflurane (2)
Novartis Pharmaceuticals (6) · Mayo Clinic (3) · Clinigen, Inc. (2) · Erasmus Medical Center (2) · GT Medical Technologies, Inc. (2) · Hospices Civils de Lyon (2) · Lund University (2) · Merck Sharp & Dohme LLC (2) · Samsung Medical Center (2) · University Medical Center Groningen (2) · Weill Medical College of Cornell University (2) · Advanced Accelerator Applications (1) · Anna Cruceta (1) · Assistance Publique Hopitaux De Marseille (1) · Beijing GoBroad Hospital (1)
United States (29) · Netherlands (12) · France (10) · China (9) · Germany (8) · Italy (8) · Canada (7) · Russia (7) · South Korea (7) · Spain (7) · Poland (6) · Czechia (5) · India (5) · United Kingdom (5) · Australia (4)
A A. Franken, MD PhD (1) · Axel Hauschild, MD (1) · Bas Havekes, MD PhD (1) · Boni E Elewski, MD (1) · C B. Brouwer, MD PhD (1) · Carol L Shields, MD (1) · E M. Eekhoff, MD PhD (1) · EnXiao Li, PhD (1) · Erna Snellman, Professor (1) · Fang Yongjun, Ph.D (1)
PMID 17917842, PMID 19574236, PMID 19645909, PMID 22027076, PMID 14557435, PMID 16235676, PMID 18607963, PMID 21319349, PMID 21456091, PMID 23195688, PMID 23959584, PMID 2496905, PMID 25205361, PMID 25243546, PMID 25587648, PMID 25677941, PMID 26481741, PMID 27875519, PMID 28535181, PMID 30028528, PMID 30053905, PMID 30821848, PMID 31714582, PMID 31872324, PMID 32503055, PMID 32712149, PMID 32792133, PMID 32800304, PMID 33159114, PMID 33411058, PMID 33527610, PMID 34171339, PMID 35090129, PMID 35132704, PMID 35191944, PMID 35230185, PMID 35275019, PMID 35403447, PMID 35661809, PMID 35671519, PMID 35724357, PMID 35838207, PMID 36116420, PMID 36239858, PMID 37533236, PMID 38553990, PMID 38939518, PMID 38995891, PMID 39539913, PMID 39830821
2019 (2), 2023 (2), 2017 (1), 2018 (1)